首页 > 最新文献

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America最新文献

英文 中文
Hospitalized patients with severe COVID-19 during the Omicron wave in Israel – benefits of a fourth vaccine dose 以色列奥米克隆波期间患有严重COVID-19的住院患者-第四剂疫苗的益处
Tal Brosh-Nissimov, K. Hussein, Y. Wiener‐Well, E. Orenbuch-Harroch, Meital Elbaz, Shelly Lipman-Arens, Y. Maor, Y. Yagel, B. Chazan, M. Hershman-Sarafov, G. Rahav, O. Zimhony, Adi Zaidman Shimshovitz, M. Chowers
Importance: Waning immunity against COVID-19 in parallel with an increased incidence during the Omicron outbreak led the Israeli Ministry of Health to recommend a second booster dose of BNT162b2 (Pfizer) to high-risk individuals. Israel was the first country to recommend this, allowing evaluation of the added protection of a fourth vaccine dose to hospitalized patients with severe diseases. Objective: To assess the effect of a fourth dose for hospitalized patients with severe/critical breakthrough COVID-19. Design: A cohort study of hospitalized adults from 01/15/2022-01/31/2022. Settings: A multi center study of 14 medical centers in Israel. Participants: Hospitalized adult patients with PCR-confirmed severe/critical COVID-19. Excluded were patients lacking data on vaccination status. Exposure: Cases were divided according to the total number of vaccine doses received up to 7 days before diagnosis. Unvaccinated adults and single-dose recipients were grouped into an unvaccinated group. Main Outcome: A composite of mechanical ventilation or in-hospital death was defined as poor outcome. Outcomes were compared between 3- and 4-dose vaccinees. Results: Included were 1,049 patients with severe/critical COVID-19, median age 80 (IQR 69-87), 51% males. Among them, 360 unvaccinated, 34, 172, 386 and 88 were after 1, 2, 3 or 4 doses, respectively. Patients after 3 doses were older, had more males and immunosuppression, but with similar outcomes, 49% vs. 51% compared to unvaccinated patients (p=0.72). Patients after 4 doses were similarly older and immunosuppressed, but had improved outcomes compared to unvaccinated patients, 34% vs. 51% (p<0.01). We proceeded to examine independent predictors for poor outcome in fully-vaccinated patients with either 3 doses given a median of 161 (IQR 147-168) days earlier, or 4 doses given a median of 14 (IQR 10-18) days before diagnoses. Receipt of the fourth dose conferred significant protection: OR 0.51 (95%CI 0.30.87). Conclusion and Relevance: Within a population of hospitalized patients with severe/critical breakthrough COVID-19, a recent fourth dose was associated with significant protection against mechanical ventilation or death, compared to fully-vaccinated single boosted individuals.
重要性:在Omicron爆发期间,对COVID-19的免疫力下降,同时发病率增加,导致以色列卫生部向高危人群推荐第二剂BNT162b2(辉瑞)加强剂。以色列是第一个提出这一建议的国家,它允许评估第四剂疫苗对住院重症患者的额外保护作用。目的:评价新冠肺炎重症/危重型突破住院患者第四次用药的效果。设计:对2022年1月15日至2022年1月31日住院的成年人进行队列研究。环境:以色列14个医疗中心的多中心研究。参与者:经pcr确诊的重症/危重型COVID-19住院成人患者。排除了缺乏疫苗接种状况数据的患者。暴露:根据诊断前7天内接受的疫苗剂量总数对病例进行分类。未接种疫苗的成年人和单次接种者被分为未接种组。主要转归:机械通气或院内死亡的组合被定义为不良转归。比较了3剂和4剂疫苗接种者的结果。结果:纳入重症/危重型COVID-19患者1049例,中位年龄80岁(IQR 69 ~ 87),男性占51%。其中未接种者360人,接种1剂、2剂、3剂、4剂者分别为34人、172人、386人、88人。接种3次疫苗的患者年龄较大,男性较多,免疫抑制较多,但与未接种疫苗的患者相比,结果相似,分别为49%和51% (p=0.72)。接种4次疫苗的患者同样年龄较大且免疫抑制,但与未接种疫苗的患者相比,结果有所改善,34% vs. 51% (p<0.01)。我们进一步检查了完全接种疫苗的患者预后不良的独立预测因素,这些患者在诊断前3次接种的中位数为161 (IQR 147-168)天,或4次接种的中位数为14 (IQR 10-18)天。接受第四剂具有显著的保护作用:OR 0.51 (95%CI 0.30.87)。结论和相关性:在COVID-19重症/危重突破住院患者人群中,与完全接种单次疫苗的个体相比,最近接种的第四剂疫苗与防止机械通气或死亡的显着保护相关。
{"title":"Hospitalized patients with severe COVID-19 during the Omicron wave in Israel – benefits of a fourth vaccine dose","authors":"Tal Brosh-Nissimov, K. Hussein, Y. Wiener‐Well, E. Orenbuch-Harroch, Meital Elbaz, Shelly Lipman-Arens, Y. Maor, Y. Yagel, B. Chazan, M. Hershman-Sarafov, G. Rahav, O. Zimhony, Adi Zaidman Shimshovitz, M. Chowers","doi":"10.1101/2022.04.24.22274237","DOIUrl":"https://doi.org/10.1101/2022.04.24.22274237","url":null,"abstract":"Importance: Waning immunity against COVID-19 in parallel with an increased incidence during the Omicron outbreak led the Israeli Ministry of Health to recommend a second booster dose of BNT162b2 (Pfizer) to high-risk individuals. Israel was the first country to recommend this, allowing evaluation of the added protection of a fourth vaccine dose to hospitalized patients with severe diseases. Objective: To assess the effect of a fourth dose for hospitalized patients with severe/critical breakthrough COVID-19. Design: A cohort study of hospitalized adults from 01/15/2022-01/31/2022. Settings: A multi center study of 14 medical centers in Israel. Participants: Hospitalized adult patients with PCR-confirmed severe/critical COVID-19. Excluded were patients lacking data on vaccination status. Exposure: Cases were divided according to the total number of vaccine doses received up to 7 days before diagnosis. Unvaccinated adults and single-dose recipients were grouped into an unvaccinated group. Main Outcome: A composite of mechanical ventilation or in-hospital death was defined as poor outcome. Outcomes were compared between 3- and 4-dose vaccinees. Results: Included were 1,049 patients with severe/critical COVID-19, median age 80 (IQR 69-87), 51% males. Among them, 360 unvaccinated, 34, 172, 386 and 88 were after 1, 2, 3 or 4 doses, respectively. Patients after 3 doses were older, had more males and immunosuppression, but with similar outcomes, 49% vs. 51% compared to unvaccinated patients (p=0.72). Patients after 4 doses were similarly older and immunosuppressed, but had improved outcomes compared to unvaccinated patients, 34% vs. 51% (p<0.01). We proceeded to examine independent predictors for poor outcome in fully-vaccinated patients with either 3 doses given a median of 161 (IQR 147-168) days earlier, or 4 doses given a median of 14 (IQR 10-18) days before diagnoses. Receipt of the fourth dose conferred significant protection: OR 0.51 (95%CI 0.30.87). Conclusion and Relevance: Within a population of hospitalized patients with severe/critical breakthrough COVID-19, a recent fourth dose was associated with significant protection against mechanical ventilation or death, compared to fully-vaccinated single boosted individuals.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90527902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022 估计2022年1月1日至3月16日纽约市Omicron (BA.1)激增期间SARS-CoV-2感染的流行率
S. Qasmieh, M. Robertson, C. Teasdale, S. Kulkarni, D. Nash
In a population-based survey of NYC adults, we assessed positive SARS-CoV-2 tests (including via exclusive at-home testing) and possible cases among untested respondents. An estimated 27.4% (95%CI: 22.8%-32.0%) or 1.8 million adults (95%CI: 1.6-2.1 million) had SARS-CoV-2 infection. SARS-CoV-2 prevalence was high among groups that are more vulnerable to severe SARS-CoV-2 and death, including unvaccinated persons (21.7%, 95%CI 9.6%-33.8%) and those aged 65+ (17.8%, 95%CI 10.2-25.4%). Population-based representative surveys are an important adjunct surveillance tool to standard testing-based SARS-CoV-2 surveillance.
在对纽约市成年人进行的一项基于人群的调查中,我们评估了SARS-CoV-2检测阳性(包括通过独家在家检测)和未经检测的受访者中的可能病例。估计有27.4% (95%CI: 22.8%-32.0%)或180万成年人(95%CI: 160 - 210万)感染了SARS-CoV-2。SARS-CoV-2在严重易感人群和死亡人群中患病率较高,包括未接种疫苗人群(21.7%,95%CI 9.6%-33.8%)和65岁以上人群(17.8%,95%CI 10.2-25.4%)。基于人群的代表性调查是标准的基于检测的SARS-CoV-2监测的重要辅助监测工具。
{"title":"Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022","authors":"S. Qasmieh, M. Robertson, C. Teasdale, S. Kulkarni, D. Nash","doi":"10.1101/2022.04.23.22274214","DOIUrl":"https://doi.org/10.1101/2022.04.23.22274214","url":null,"abstract":"In a population-based survey of NYC adults, we assessed positive SARS-CoV-2 tests (including via exclusive at-home testing) and possible cases among untested respondents. An estimated 27.4% (95%CI: 22.8%-32.0%) or 1.8 million adults (95%CI: 1.6-2.1 million) had SARS-CoV-2 infection. SARS-CoV-2 prevalence was high among groups that are more vulnerable to severe SARS-CoV-2 and death, including unvaccinated persons (21.7%, 95%CI 9.6%-33.8%) and those aged 65+ (17.8%, 95%CI 10.2-25.4%). Population-based representative surveys are an important adjunct surveillance tool to standard testing-based SARS-CoV-2 surveillance.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85548093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Correction to: Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. 更正:在瑞士HIV队列研究中,变性女性作为流行病学上独特的危险群体的识别和特征。
Huyen Nguyen, B. Hampel, David Garcia Nuñez, M. Battegay, A. Hachfeld, E. Bernasconi, A. Calmy, M. Cavassini, P. Vernazza, J. Fellay, Hannes Rudolph, M. Huber, K. Leuzinger, M. Perreau, A. Scherrer, A. Ramette, S. Yerly, H. Günthard, R. Kouyos, K. Kusejko
{"title":"Correction to: Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group.","authors":"Huyen Nguyen, B. Hampel, David Garcia Nuñez, M. Battegay, A. Hachfeld, E. Bernasconi, A. Calmy, M. Cavassini, P. Vernazza, J. Fellay, Hannes Rudolph, M. Huber, K. Leuzinger, M. Perreau, A. Scherrer, A. Ramette, S. Yerly, H. Günthard, R. Kouyos, K. Kusejko","doi":"10.1093/cid/ciac242","DOIUrl":"https://doi.org/10.1093/cid/ciac242","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74705128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men. 修正:男男性行为的年轻男性接种疫苗或自然感染后的人乳头瘤病毒抗体水平。
E. Chow, C. Fairley, H. Zou, Rebecca Wigan, S. Garland, A. Cornall, Steph Atchison, S. Tabrizi, Marcus Y. Chen
{"title":"Correction to: Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men.","authors":"E. Chow, C. Fairley, H. Zou, Rebecca Wigan, S. Garland, A. Cornall, Steph Atchison, S. Tabrizi, Marcus Y. Chen","doi":"10.1093/cid/ciac245","DOIUrl":"https://doi.org/10.1093/cid/ciac245","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80246766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Prevalence of Mycobacterium tuberculosis in Sputum and Reported Symptoms Among Clinic Attendees Compared With a Community Survey in Rural South Africa 更正:与南非农村社区调查相比,临床参与者痰中结核分枝杆菌的患病率和报告的症状
I. Govender, A. Karat, S. Olivier, K. Baisley, Peter G. Beckwith, N. Dayi, J. Dreyer, D. Gareta, R. Gunda, K. Kielmann, O. Koole, N. Mhlongo, Tshwaraganang H Modise, S. Moodley, Xolile Mpofana, T. Ndung’u, D. Pillay, M. Siedner, T. Smit, Ashmika Surujdeen, E. Wong, A. Grant
{"title":"Correction to: Prevalence of Mycobacterium tuberculosis in Sputum and Reported Symptoms Among Clinic Attendees Compared With a Community Survey in Rural South Africa","authors":"I. Govender, A. Karat, S. Olivier, K. Baisley, Peter G. Beckwith, N. Dayi, J. Dreyer, D. Gareta, R. Gunda, K. Kielmann, O. Koole, N. Mhlongo, Tshwaraganang H Modise, S. Moodley, Xolile Mpofana, T. Ndung’u, D. Pillay, M. Siedner, T. Smit, Ashmika Surujdeen, E. Wong, A. Grant","doi":"10.1093/cid/ciac244","DOIUrl":"https://doi.org/10.1093/cid/ciac244","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84178742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Correction to: Fine-scale Spatiotemporal Mapping of Asymptomatic and Clinical Plasmodium falciparum Infections: Epidemiological Evidence for Targeted Malaria Elimination Interventions 修正:无症状和临床恶性疟原虫感染的精细时空映射:目标疟疾消除干预的流行病学证据
Makhtar Niang, M. Sandfort, Adja Fatou Mbodj, B. Diouf, C. Talla, J. Faye, Rokhaya Sané, L. Thiam, A. Thiam, A. Badiane, I. Vigan-Womas, N. Diagne, Fatoumata Diène Sarr, I. Mueller, C. Sokhna, M. White, Aissatou Toure-Balde
{"title":"Correction to: Fine-scale Spatiotemporal Mapping of Asymptomatic and Clinical Plasmodium falciparum Infections: Epidemiological Evidence for Targeted Malaria Elimination Interventions","authors":"Makhtar Niang, M. Sandfort, Adja Fatou Mbodj, B. Diouf, C. Talla, J. Faye, Rokhaya Sané, L. Thiam, A. Thiam, A. Badiane, I. Vigan-Womas, N. Diagne, Fatoumata Diène Sarr, I. Mueller, C. Sokhna, M. White, Aissatou Toure-Balde","doi":"10.1093/cid/ciac146","DOIUrl":"https://doi.org/10.1093/cid/ciac146","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81335149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study 更正:接受瑞德西韦和地塞米松治疗的2019冠状病毒病(COVID-19)住院患者的生存率提高一项全国性人群队列研究
T. Benfield, J. Bodilsen, C. Brieghel, Z. Harboe, M. Helleberg, C. Holm, S. Israelsen, Janne Jensen, T. Jensen, I. Johansen, S. Johnsen, B. L. Madsen, J. Lundgren, C. Meyer, R. Mohey, L. Pedersen, H. Nielsen, S. L. Nielsen, N. Obel, L. Omland, D. Podlekareva, B. Poulsen, P. Ravn, H. Sandholdt, Jonathan Starling, M. Storgaard, C. Søborg, O. Søgaard, Torben Tranborg, L. Wiese, H. R. Christensen
{"title":"Correction to: Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study","authors":"T. Benfield, J. Bodilsen, C. Brieghel, Z. Harboe, M. Helleberg, C. Holm, S. Israelsen, Janne Jensen, T. Jensen, I. Johansen, S. Johnsen, B. L. Madsen, J. Lundgren, C. Meyer, R. Mohey, L. Pedersen, H. Nielsen, S. L. Nielsen, N. Obel, L. Omland, D. Podlekareva, B. Poulsen, P. Ravn, H. Sandholdt, Jonathan Starling, M. Storgaard, C. Søborg, O. Søgaard, Torben Tranborg, L. Wiese, H. R. Christensen","doi":"10.1093/cid/ciac243","DOIUrl":"https://doi.org/10.1093/cid/ciac243","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90339563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Correction to: Reply to van Deun and Decroo. 更正:回复范德恩和德克罗。
J. P. Cegielski, Z. Udwadia, P. Viiklepp, J. Yim, D. Menzies
{"title":"Correction to: Reply to van Deun and Decroo.","authors":"J. P. Cegielski, Z. Udwadia, P. Viiklepp, J. Yim, D. Menzies","doi":"10.1093/cid/ciac241","DOIUrl":"https://doi.org/10.1093/cid/ciac241","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73639161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usage and awareness of antiviral medications for COVID-19 COVID-19抗病毒药物的使用和认识
N. Kojima, J. Klausner
We surveyed people that recently tested positive for SARS-CoV-2 to assess the frequency and correlates of early treatment seeking behavior. Among high risk respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection. More public outreach is needed to raise awareness of the benefits of treatment for COVID-19.
我们调查了最近SARS-CoV-2检测呈阳性的人,以评估早期寻求治疗行为的频率和相关性。在高风险受访者中,66.0%的人知道COVID-19的治疗方法,36.3%的人寻求治疗,但只有1.7%的人报告使用抗病毒药物治疗SARS-CoV-2感染。需要更多的公众宣传,以提高对COVID-19治疗益处的认识。
{"title":"Usage and awareness of antiviral medications for COVID-19","authors":"N. Kojima, J. Klausner","doi":"10.1101/2022.04.21.22274155","DOIUrl":"https://doi.org/10.1101/2022.04.21.22274155","url":null,"abstract":"We surveyed people that recently tested positive for SARS-CoV-2 to assess the frequency and correlates of early treatment seeking behavior. Among high risk respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection. More public outreach is needed to raise awareness of the benefits of treatment for COVID-19.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91483453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study 更正:一项多中心观察性研究:是否、何时以及如何使用利福平治疗急性葡萄球菌性假体周围关节感染
M. Beldman, C. Löwik, Á. Soriano, Laila Albiach, W. Zijlstra, B. Knobben, P. Jutte, R. Sousa, A. Carvalho, K. Goswami, J. Parvizi, K. Belden, M. Wouthuyzen-Bakker
{"title":"Correction to: If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study","authors":"M. Beldman, C. Löwik, Á. Soriano, Laila Albiach, W. Zijlstra, B. Knobben, P. Jutte, R. Sousa, A. Carvalho, K. Goswami, J. Parvizi, K. Belden, M. Wouthuyzen-Bakker","doi":"10.1093/cid/ciac149","DOIUrl":"https://doi.org/10.1093/cid/ciac149","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80139878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1